Nanogels for Oligonucleotide Delivery to the Brain

Bioconjugate Chemistry

Volumn 15, Issue 1, 2004, Pages 50-60

  Vinogradov, Serguei V ^a   Batrakova, Elena V ^a   Kabanov, Alexander V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; BLOOD VESSELS; MAMMALS; NANOSTRUCTURED MATERIALS; NEURODEGENERATIVE DISEASES; OLIGONUCLEOTIDES; POLYELECTROLYTES; POLYETHYLENE GLYCOLS; SYNTHESIS (CHEMICAL);

BLOOD-BRAIN BARRIER; BRAIN MICROVESSELS; CENTRAL NERVOUS SYSTEMS; DIAGNOSTIC MODALITY; NANOGELS; NANOSCALE NETWORKS; NEURODEGENERATIVE DISORDERS; POLY(ETHYLENIMINE); SYSTEMIC DELIVERIES; THERAPEUTIC MODALITY;

ENDOTHELIAL CELLS;

INSULIN; MACROGOL; NANOPARTICLE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE; POLYELECTROLYTE; POLYETHYLENEIMINE; TRANSFERRIN;

ADOLESCENT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN; BRAIN MICROCIRCULATION; CATTLE; CHEMICAL MODIFICATION; DEGENERATIVE DISEASE; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; ENDOTHELIUM CELL; ENZYMATIC DEGRADATION; FEMALE; GEL; IN VITRO STUDY; LIVER; MACROMOLECULE; MODEL; MONOLAYER CULTURE; MOUSE; NANOGEL; NONHUMAN; NUCLEOTIDE METABOLISM; NUCLEOTIDE TRANSPORT; PARTICLE SIZE; SPLEEN; SURFACE PROPERTY; SYNTHESIS; TISSUE DISTRIBUTION; TRANSCYTOSIS;

ANIMALIA; BOS TAURUS; BOVINAE;

EID: 0842263616     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc034164r     Document Type: Article

References (38)

1. Boado, R. J., Tsukamoto, H., and Pardridge, W. M. (1998) Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J. Pharm. Sci. 87, 1308-1315.
2. Seidman, S., Eckstein, F., Grifman, M., and Soreq, H. (1999) Antisense technologies have a future fighting neurodegenerative diseases. Antisense Nucleic Acid Drug Dev. 9, 333-340.
3. Field, A. K. (1999) Oligonucleotides as inhibitors of human immunodeficiency virus. Curr. Opin. Mol. Ther. 1, 323-331.
4. Ho, S. P., and Hartig, P. R. (1999) Antisense oligonucleotides for target validation in the CNS. Curr. Opin. Mol. Ther. 1, 336-343.
5. McCarthy, M. M., Auger, A. P., Mong, J. A., Sickel, M. J., and Davis, A. M. (2000) Antisense oligodeoxynucleotides as a tool in developmental neuroendocrinology. Methods 22, 239-248.
6. Wang, H., Prasad, G., Buolamwini, J. K., and Zhang, R. (2001) Antisense anticancer oligonucleotide therapeutics. Curr Cancer Drug Targets 1, 177-196.
7. Dias, N. and Stein, C. A. (2002) Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur. J. Pharm. Biopharm. 54, 263-269.
8. Broaddus, W. C., Prabhu, S. S., Wu-Pong, S., Gillies, G. T. and Fillmore, H. (2000) Strategies for the design and delivery of antisense oligonucleotides in central nervous system. Methods Enzymol. 314, 121-135.
9. Matsuo, H., Okamura, T., Chen, J., Takanaga, H., Ohtani, H., Kaneda, Y., Naito, M., Tsuruo, T. and Sawada, Y. (2000) Efficient introduction of macromolecules and oligonucleotides into brain capillary endothelial cells using HVJ-liposomes. J. Drug Target. 8, 207-216.
10. Merdan, T., Kopecek, J. and Kissel, T. (2002) Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Delivery Rev. 54, 715-758.
11. Brigger, I., Dubernet, C. and Couvreur, P. (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv. Rev. 54, 631-651.
12. Pardridge, W. M. (2002) Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discovery 1, 131-139.
13. Kreuter, J. (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Delivery Rev 47, 65-81.
14. Pardridge, W. M., Eisenberg, J., and Yang, J. (1985) Human blood-brain barrier insulin receptor. J Neurochem. 44, 1771-1778.
15. Pardridge, W. M., Eisenberg, J., and Yang, J. (1987) Human blood-brain barrier transferrin receptor. Metabolism 36, 892-895.
16. Zhang, Y., Jeong Lee, H., Boado, R. J., and Pardridge, W. M. (2002) Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med. 4, 183-194.
17. Kabanov, A. V. and Vinogradov, S. V. (2001), Supratek Pharma, Inc., US.
18. Vinogradov, S. V., Batrakova, E. V., and Kabanov, A. V. (1999) Poly(ethylene glycol)-polyethyleneimine NanoGel particles: novel drug delivery systems for antisense oligonucleotides. Coll. Surf. B: Biointerfaces 16, 291-304.
19. Lemieux, P., Vinogradov, S. V., Gebhart, C. L., Guerin, N., Paradis, G., Nguyen, H. K., Ochietti, B., Suzdaltseva, Y. G., Bartakova, E. V., Bronich, T. K., St-Pierre, Y., Alakhov, V. Y., and Kabanov, A. V. (2000) Block and graft copolymers and NanoGel copolymer networks for DNA delivery into cell. J. Drug Target. 8, 91-105.
20. Vinogradov, S. V., Bronich, T. K., and Kabanov, A. V. (2002) Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Delivery Rev 54, 135-147.
21. Nag, A., Mitra, G., and Ghosh, P. C. (1996) A colorimetric assay for estimation of poly(ethylene glycol) and poly(ethylene glycol)ated protein using ammonium ferrothiocyanate. Anal. Biochem 237, 224-231.
22. Mock, D. M., Lankford, G., and Horowitz, P. (1988) A study of the interaction of avidin with 2-anilinonaphthalene-6-sulfonic acid as a probe of the biotin binding site. Biochim Biophys Acta 956, 23-29.
23. Ledoan, T., Auger, R., Benjahad, A., and Tenu, J. P. (1999) High specific radioactivity labeling of oligonucleotides with 3H-succinimidyl propionate. Nucleosides Nucleotides 18, 277-289.
24. Miller, D. W., Audus, K. L., and Borchardt, R. T. (1992) Application of cultured bovine brain endothelial cells of the brain microvasculature in the study of the blood-brain barrier. J. Tissue Cult. Methods 14, 217-224.
25. Ferrari, M., Fornasiero, M. C., and Isetta, A. M. (1990) MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods 131, 165-172.
26. Batrakova, E. V., Li, S., Miller, D. W., and Kabanov, A. V. (1999) Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16, 1366-1372.
27. Bourque, A. J., and Cohen, A. S. (1993) Quantitative analysis of phosphorothioate oligonucleotides in biological fluids using fast anion-exchange chromatography. J Chromatogr. 617, 43-49.
28. Batrakova, E. V., Miller, D. W., Li, S., Alakhov, V. Y., Kabanov, A. V., and Elmquist, W. F. (2001) Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 296, 551-557.
29. Vinogradov, S. V., Bronich, T. K. and Kabanov, A. V. (1998) Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. Bioconjugate Chem. 9, 805-812.
30. Bronich, T., Vinogradov, S. and Kabanov, A. V. (2001) Interaction of nanosized copolymer networks with oppositely charged amphiphilic molecules. Nano Lett. 1, 535-540.
31. Ogris, M., Brunner, S., Schuller, S., Kircheis, R., Wagner, E. (1999) PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6, 595-605.
32. Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B. and Behr, J. P. (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci U. S. A. 92, 7297-7301.
33. Helander, I. M., Latva-Kala, K. and Lounatmaa, K. (1998) Permeabilizing action of polyethyleneimine on Salmonella typhimurium involves disruption of the outer membrane and interactions with lipopolysaccharide. Microbiology 144 (Pt 2), 385-390.
34. Banks, W. A., Farr, S. A., Butt, W., Kumar, V. B., Franko, M. W. and Morley, J. E. (2001) Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J. Pharmacol. Exp. Ther. 297, 1113-1121.
35. Geary, R. S., Yu, R. Z. and Levin, A. A. (2001) Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs 2, 562-573.
36. Wu, D., Boado, R. J. and Pardridge, W. M. (1996) Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J. Pharmacol. Exp. Ther. 276, 206-211.
37. Srinivasan, S. K., Tewary, H. K. and Iversen, P. L. (1995) Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res. Dev. 5, 131-139.
38. Sawai, K., Miyao, T., Takakura, Y. and Hashida, M. (1995) Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney. Antisense Res. Dev. 5, 279-287.